In last trading session, Virax Biolabs Group Ltd (NASDAQ:VRAX) saw 0.5 million shares changing hands with its beta currently measuring 1.71. Company’s recent per share price level of $1.81 trading at $0.08 or 4.62% at ring of the bell on the day assigns it a market valuation of $4.27M. That closing price of VRAX’s stock is at a discount of -201.1% from its 52-week high price of $5.45 and is indicating a premium of 66.85% from its 52-week low price of $0.60. Taking a look at company’s average trading volume volume of 1.39 million if we extend that period to 3-months.
Virax Biolabs Group Ltd (NASDAQ:VRAX) trade information
Upright in the green during last session for gaining 4.62%, in the last five days VRAX remained trading in the red while hitting it’s week-highest on Monday, 06/10/24 when the stock touched $1.81 price level, adding 9.5% to its value on the day. Virax Biolabs Group Ltd’s shares saw a change of 23.97% in year-to-date performance and have moved -8.12% in past 5-day. Virax Biolabs Group Ltd (NASDAQ:VRAX) showed a performance of 130.57% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRAX Dividends
Virax Biolabs Group Ltd is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
